Reuters

Nvidia deepens bets on AI in drug discovery with Recursion investment

Recursion, whose advisers include AI pioneer Yoshua Bengio, will use its biological and chemical datasets exceeding 23,000 terabytes to train AI models on Nvidia's cloud platform. Sign up here. Nvidia ...
Nasdaq

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Bloomberg L.P.

AI Drug Discovery Firm Recursion Surges Following $50 Million Nvidia Investment

The latest sign of investors’ unrelenting demand for all things artificial intelligence related: a record rally in drug discovery firm Recursion Pharmaceuticals Inc. following an investment from ...
Reuters

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

NEW YORK, Aug 8 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab, a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival ...
The Motley Fool

Recursion Pharmaceuticals Is Going Big on AI. Here's Why It Could Be Worth Buying

Recursion Pharmaceuticals just acquired a pair of AI-related biotechs. This could bolster its drug discovery capabilities and better help its clients. But the stock is high-risk and requires a ...
The Motley Fool

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...